Emergent Biosolutions Stock Today
| EBS Stock | USD 2.04 0.18 9.68% |
Performance3 of 100
| Odds Of DistressLess than 39
|
Emergent Biosolutions is selling for under 2.04 as of the 20th of April 2024; that is 9.68 percent increase since the beginning of the trading day. The stock's lowest day price was 1.84. Emergent Biosolutions has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Emergent Biosolutions are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of March 2024 and ending today, the 20th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of November 2006 | Category Healthcare | Classification Health Care |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. The company has 52.39 M outstanding shares of which 5.7 M shares are currently shorted by investors with about 2.64 days to cover. More on Emergent Biosolutions
Moving together with Emergent Stock
| 0.64 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.64 | GRTX | Galera Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.61 | JSPRW | Jasper Therapeutics | PairCorr |
Moving against Emergent Stock
| 0.51 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
| 0.48 | MRKR | Marker Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Emergent Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Emergent Biosolutions' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Emergent Biosolutions or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Daniel AbdunNabi | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Austrian Traded Index, HNX, HNX MidSmall Cap, ATX Prime, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Emergent Biosolutions report their recommendations after researching Emergent Biosolutions' financial statements, talking to executives and customers, or listening in on Emergent Biosolutions' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Emergent Biosolutions. The Emergent consensus assessment is calculated by taking the average forecast from all of the analysts covering Emergent Biosolutions. | |||||
Emergent Biosolutions' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Emergent Biosolutions' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. Emergent Biosolutions' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Emergent Biosolutions' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest. Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Emergent Biosolutions' financial leverage. It provides some insight into what part of Emergent Biosolutions' total assets is financed by creditors.
| |||||
Emergent Biosolutions (EBS) is traded on New York Stock Exchange in USA. It is located in 400 Professional Drive, Gaithersburg, MD, United States, 20879 and employs 1,600 people. Emergent Biosolutions is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 106.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Emergent Biosolutions's market, we take the total number of its shares issued and multiply it by Emergent Biosolutions's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Emergent Biosolutions runs under Biotechnology sector within Health Care industry. The entity has 52.39 M outstanding shares of which 5.7 M shares are currently shorted by investors with about 2.64 days to cover.
Emergent Biosolutions has about 642.6 M in cash with (34.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Emergent Biosolutions Probability Of Bankruptcy
Ownership AllocationEmergent Biosolutions retains a total of 52.39 Million outstanding shares. The majority of Emergent Biosolutions outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Emergent Biosolutions to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Emergent Biosolutions. Please pay attention to any change in the institutional holdings of Emergent Biosolutions as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Emergent Ownership Details
Emergent Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Emergent Biosolutions jumping above the current price in 90 days from now is about 64.97%. The Emergent Biosolutions probability density function shows the probability of Emergent Biosolutions stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.7232 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Emergent Biosolutions will likely underperform. Additionally, emergent Biosolutions has an alpha of 0.3603, implying that it can generate a 0.36 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Emergent Biosolutions to move above the current price in 90 days from now is about 64.97 (This Emergent Biosolutions probability density function shows the probability of Emergent Stock to fall within a particular range of prices over 90 days) .
Emergent Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Emergent Biosolutions that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Emergent Biosolutions' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Emergent Biosolutions' value.| Instituion | Recorded On | Shares | |
| State Street Corporation | 2023-12-31 | 1.1 M | |
| Two Sigma Investments Llc | 2023-12-31 | 1 M | |
| D. E. Shaw & Co Lp | 2023-09-30 | 936.5 K | |
| Prescott Group Capital Management Llc | 2023-12-31 | 853.3 K | |
| Assenagon Asset Management Sa | 2023-12-31 | 834.4 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 658.2 K | |
| Qube Research & Technologies | 2023-12-31 | 621.2 K | |
| Bridgeway Capital Management, Llc | 2023-12-31 | 616.5 K | |
| Renaissance Technologies Corp | 2023-12-31 | 547.3 K | |
| Blackrock Inc | 2023-12-31 | 9.4 M | |
| Vanguard Group Inc | 2023-12-31 | 3 M |
Emergent Biosolutions Historical Income Statement
Emergent Biosolutions Income Statement is one of the three primary financial statements used for reporting Emergent's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Emergent Biosolutions revenue and expense. Emergent Biosolutions Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Emergent Biosolutions' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 45 M in 2024, despite the fact that Operating Income is likely to grow to (181.4 M). View More FundamentalsEmergent Stock Against Markets
Picking the right benchmark for Emergent Biosolutions stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Emergent Biosolutions stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Emergent Biosolutions is critical whether you are bullish or bearish towards Emergent Biosolutions at a given time. Please also check how Emergent Biosolutions' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Emergent Biosolutions without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Emergent Biosolutions Corporate Directors
Emergent Biosolutions corporate directors refer to members of an Emergent Biosolutions board of directors. The board of directors generally takes responsibility for the Emergent Biosolutions' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Emergent Biosolutions' board members must vote for the resolution. The Emergent Biosolutions board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Sue Bailey | Independent Director | Profile | |
| Jerome Hauer | Independent Director | Profile | |
| Kathryn Zoon | Independent Director | Profile | |
| Seamus Mulligan | Director | Profile |
How to buy Emergent Stock?
Before investing in Emergent Biosolutions, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Emergent Biosolutions. To buy Emergent Biosolutions stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Emergent Biosolutions. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Emergent Biosolutions stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Emergent Biosolutions stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Emergent Biosolutions stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Emergent Biosolutions, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.
Already Invested in Emergent Biosolutions?
The danger of trading Emergent Biosolutions is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Emergent Biosolutions is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Emergent Biosolutions. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Emergent Biosolutions is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Emergent Biosolutions is a strong investment it is important to analyze Emergent Biosolutions' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Emergent Biosolutions' future performance. For an informed investment choice regarding Emergent Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Emergent Stock analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.022 | Earnings Share (14.85) | Revenue Per Share 20.494 | Quarterly Revenue Growth (0.16) | Return On Assets (0.05) |
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine if Emergent Biosolutions is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.